Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > Long-Term Debt

Rigel Pharmaceuticals Long-Term Debt Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly Long-Term Debt from 2019 to 2020.
  • Rigel Pharmaceuticals Long-Term Debt for the quarter ending June 06, 2020 was $20m a 50.60% increase of 10m year over year
  • Rigel Pharmaceuticals Long-Term Debt for the last 12 months ending June 06, 2020 was $20m a 50.60% increase of 10m year over year
Other Cash Flow Metrics:
  • Rigel Pharmaceuticals Cash Flow from Operations for the quarter ending December 12, 2018 was $12m a 300.91% increase of 35m year over year
  • Rigel Pharmaceuticals Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $1m a 1,495.75% increase of 15m year over year
  • Rigel Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $5m a 26.33% increase of 1m year over year
View Chart On Koyfin

Quarterly RIGL Long-Term Debt Data

06/2020$20m
03/2020$10m
12/2019$10m
09/2019$10m

Annual RIGL Long-Term Debt Data

2019$10m